Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
Leung Li(Chinese University of Hong Kong), Winnie Yeo(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Edwin P. Hui(Johns Hopkins University), Kit F. Lee(Chinese University of Hong Kong), Simon C.H. Yu(National Yang Ming Chiao Tung University), J. Hui(Chinese University of Hong Kong), Annette Poon(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong), Cheuk Man Chu(Chinese University of Hong Kong), Anthony T.�C. Chan(Chinese University of Hong Kong), Brigette Ma(Chinese University of Hong Kong), Nelson L.S. Tang(Chinese University of Hong Kong), Frankie Mo(Chinese University of Hong Kong), Linda K. S. Leung(Chinese University of Hong Kong), Jane Koh(Chinese University of Hong Kong)
Cited by 53
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k